Clinical trials: Chorea, Huntington
Huntington Disease
Synaptic Density and Progression of Huntington's Disease.
AIM: To assess synaptic density and to investigate the potential relationship of regional synaptic loss with motor and non-motor symptoms and with disease progression in the human brain in vivo in patients with HD.
- Trial name
- NCT04701580
- Testing
- 11C-UCB-J PET-CT, 18F-FDG PET-MR
- Where
- Belgium
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Alzheimer's Disease, Huntington's Disease
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.
- Trial name
- NCT00931073
- Testing
- Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Parkinson Disease, Huntington Disease
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain, may be a valuable tool in the early detection, understanding, or evaluation of Parkinson disease (PD), Huntington disease (HD), Fragile…
- Conditions
- Parkinson Disease, Huntington Disease, Autistic Spectrum Disorders, Fragile X Syndrome
- Trial name
- FPEB (NCT00870974)
- Testing
- [18F]FPEB
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Huntington Disease
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Positron Emission Tomography (PET) is a functional imaging technique, which enables in vivo visualization of biological molecules expressed in human tissues.
- Trial name
- NCT05360082
- Testing
- [11C]UCB-J PET, [18F]SynVest-1 PET
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Alzheimer Disease, Stroke
Assessment of Social-emotional Functioning in Neurological Diseases
Empathy, defined as the ability to understand others emotions, is a fundamental concept in social interactions. It is a psychological phenomenon involving various separable components : (i) the ability to feel and imagine the…
- Conditions
- Alzheimer Disease, Stroke, Parkinson's Disease, Lewy Body Dementia
- Trial name
- Emotion (NCT01339130)
- Testing
- Computerized tests and Electrophysiological measurements
- Where
- France
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Huntington Disease
Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.
This study is Single arm, Single Centre trial to check the Safety and Efficacy of Bone Marrow Derived Autologous mononuclear cell {MNC} (100 Million per dose).trial to be conducted for 36 months in patients with diabetes Mellitus…
- Trial name
- BMACHC (NCT01834053)
- Testing
- autologous Stem Cell
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chaitanya Hospital, Pune
Huntington's Disease
Cognitive Assessment Battery (CAB) Beta Study
The overall objective of this study is to identify a 60 minute cognitive battery, for subsequent use in clinical trials, that detects cognitive deficits in early HD and late pre-manifest HD compared to controls, and that has a…
- Trial name
- CAB (NCT01290861)
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Huntington Disease, Alzheimer Disease
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose…
- Trial name
- NCT00788047
- Testing
- Dextromethorphan, Dimebon + Dextromethorphan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease, Huntington's Disease
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon.
- Trial name
- NCT00824590
- Testing
- Dimebon
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neurodegenerative Disorders
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases
Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription factors (1-5).
- Trial name
- NCT00874783
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Alzheimer's Disease, Mild Cognitive Impairment
Retinal Imaging in Neurodegenerative Disease
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis
- Trial name
- NCT03233646
- Testing
- Retinal and Choroidal Imaging
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Huntington Disease
Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.
A better understanding of the HD pathogenesis mechanisms may lead to a better understanding of disease pathology, progression and development of targeted therapies.
- Trial name
- NCT05224115
- Testing
- [11C]CHDI-00485180-R, [11C]CHDI-00485626
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Brain Damage, Chronic
The Effect of tDCS on Subcortical Brain Functioning
This research is being done to determine whether transcranial direct current stimulation (tDCS) can improve certain abilities related to cognition, emotion and/or physical functioning in individuals with subcortical brain damage.
- Trial name
- NCT01602276
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Huntington's Disease
Functional Imaging of Social Cognition in Premanifest Huntington's Disease
Huntington's disease (HD) is a genetic progressive fatal neurodegenerative disorder. In the western world it affects 5-10 persons per 100000. The main brain changes include the loss of brain cells in subcortical structures.
- Trial name
- FISCIP (NCT02551705)
- Testing
- functional Imaging
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Huntington Disease
Couple and Spouse Caregiver in Huntington's Disease
The objectives are to better document the psychosocial status and needs of caregiver of HD patients and understand the dyad functioning, facing the disease at various stages.
- Trial name
- COCOON (NCT04394767)
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Huntington Disease
Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN)
REGISTRY is a multi-centre, multi-national, prospective, observational study of Huntington's disease (HD) with a control group of volunteers.
- Trial name
- NCT01554033
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Parkinson Disease, Multiple System Atrophy
Research of Biomarkers in Parkinson Disease
The main goal of the GENEPARK consortium is to employ innovative haemogenomic approaches to determine gene expression profiles specific for genetic and idiopathic Parkinson's disease (PD) patients.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Huntington Disease
- Trial name
- Genepark (NCT00465790)
- Where
- 5 sites in Croatia, France and 2 more
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Brain Neuroimaging Biomarkers in Huntington Disease
Dynamic Neuroimaging Biomarkers in Huntington's Disease
There is no curative treatment available today in Huntington disease (HD) despite the identification of the mutated gene 20 years ago.
- Trial name
- HDeNERGY (NCT02639871)
- Where
- France
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Parkinson Disease, Parkinson's Disease and Parkinsonism
Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
Diagnosing Parkinson's disease (PD) depends on the clinical history of the patient and the patient's response to specific treatments such as levodopa.
- Conditions
- Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Corticobasal Degeneration
- Trial name
- NCT04925622
- Testing
- Complex eye movement exam
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Saccadous, Inc.
Huntington Disease
Impact of Apathy on Caregiving in HD. Version 1
Huntington's disease (HD) can affect motivation. People with HD may not wash often, keep their house clean and tidy, or eating healthy food.
- Trial name
- NCT05913154
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of East Anglia